


4-301



FORM PTO-1619 Expires 06/30/99 OMB 0651-0027

04-26-2001



101689336

U.S. Department of Commerce Patent and Trademark Office PATENT

11000 U.S. P.T.O. 09/03/052 04/03/01

RECORDATION FORM COVER SHEET PATENTS ONLY

TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

Submission Type

New
 Resubmission (Non-Recordation) Document ID#
 Correction of PTO Error Reel # Frame #
 Corrective Document Reel # Frame #

Conveyance Type

Assignment Security Agreement
 License Change of Name
 Merger Other
U.S. Government (For Use ONLY by U.S. Government Agencies)
 Departmental File Secret File

Conveying Party(ies)

Mark if additional names of conveying parties attached
Name (line 1) Julian Golec Execution Date 07 24 00
Name (line 2) 09834052
Second Party Name (line 1) Paul Charifson Execution Date 07 24 00
Name (line 2)

Receiving Party

Mark if additional names of receiving parties attached
Name (line 1) Vertex Pharmaceuticals Incorporated
Name (line 2)
Address (line 1) 130 Waverly Street
Address (line 2)
Address (line 3) Cambridge MA 02139-4242
If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment.)

Domestic Representative Name and Address

Enter for the first Receiving Party only.

Name Andrew S. Marks
Address (line 1) Vertex Pharmaceuticals Inc.
Address (line 2) 130 Waverly Street
Address (line 3) Cambridge, MA 02139-4242
Address (line 4)


FOR OFFICE USE ONLY

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

Mail documents to be recorded with required cover sheet(s) information to: Commissioner of Patents and Trademarks, Box Assignments, Washington, D.C. 20231

04/26/2001 JMUJELER 00000278 500725 09834052
01 PD:5A1 80.00 CH

PATENT REEL: 011708 FRAME: 0061



FORM PTO-1613
Expires 06/30/99
OMB 0651-0027

RECORDATION FORM COVER SHEET CONTINUATION PATENTS ONLY

U.S. Department of Commerce
Patent and Trademark Office
PATENT

Conveying Party(ies)

Mark if additional names of conveying parties attached

Enter additional Conveying Parties

Name (line 1)

Execution Date
Month Day Year

Name (line 2)

Execution Date
Month Day Year

Name (line 1)

Name (line 2)

Execution Date
Month Day Year

Name (line 1)

Name (line 2)

Receiving Party(ies)

Mark if additional names of receiving parties attached

Enter additional Receiving Party(ies)

Name (line 1)

If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment.)

Name (line 2)

Address (line 1)

Address (line 2)

Address (line 3)

Name (line 1)

If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative is attached. (Designation must be a separate document from Assignment.)

Name (line 2)

Address (line 1)

Address (line 2)

Address (line 3)

Application Number(s) or Patent Number(s)

Mark if additional numbers attached

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

Patent Application Number(s)

<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>

Patent Number(s)

<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>

Correspondent Name and Address Area Code and Telephone Number

Name

Address (line 1)

Address (line 2)

Address (line 3)

Address (line 4)

Pages Enter the total number of pages of the attached conveyance document including any attachments. #

Application Number(s) or Patent Number(s) Mark if additional numbers attached

Enter either the Patent Application Number or the Patent Number (DO NOT ENTER BOTH numbers for the same property).

Patent Application Number(s)			Patent Number(s)		
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
60/147,706	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

If this document is being filed together with a new Patent Application, enter the date the patent application was signed by the first named executing inventor. Month Day Year

Patent Cooperation Treaty (PCT)

Enter PCT application number PCT PCT

only if a U.S. Application Number has not been assigned. PCT PCT PCT

Number of Properties Enter the total number of properties involved. #

Fee Amount Fee Amount for Properties Listed (37 CFR 3.41): \$

Method of Payment: Enclosed Deposit Account

Deposit Account (Enter for payment by deposit account or if additional fees can be charged to the account.)

Deposit Account Number: #

Authorization to charge additional fees: Yes No

Statement and Signature

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.

Ian Robert Silverman Ian Robert Silverman April 3, 2001

Name of Person Signing Signature Date

PCT
ASSIGNMENT

I/We,

- (1) Julian Golec
- (2) Paul Charifson
- (3) Guy Brenchley

residing, respectively, at

- (1) 8 Manor Farm, Chapel Road, Ashbury, Swindon
Wiltshire SN6 8LS United Kingdom (UK.)
- (2) 8 Dartmouth Drive, Framingham
Massachusetts 01701 (U.S.A.)
- (3) 12 Boucher Close, Grove Watage,
Oxon, United Kingdom

for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to VERTEX PHARMACEUTICALS INCORPORATED a corporation organized and existing under the laws of the COMMONWEALTH OF MASSACHUSETTS and having an office and a place of business at 130 WAVERLY STREET, CAMBRIDGE, MASSACHUSETTS 02139-4242, its successors and assigns: (1) the entire right, title and interest in all countries throughout the world in and to any and all my/our inventions and discoveries disclosed in my/our International Patent Application, filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US), entitled: "CASPASE INHIBITORS AND USES THEREOF" and designating Albania (AL), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Barbados (BB), Belarus (BY), Belgium (BE), Benin (BJ), Bosnia and Herzegovina (BA), Brazil (BR), Bulgaria (BG), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), China (CN), Congo (CG), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czech Republic (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Grenada (GD), Greece (GR), Guinea (GN), Guinea-Bissau (GW), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Ireland (IE), Israel (IL), Italy (IT), Japan (JP), Kazakstan (KZ), Kenya (KE), Kyrgyzstan (KG), Latvia (LV), Lesotho (LS), Liberia (LR), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), former Yugoslav Republic of Macedonia (MK), Malawi (MW), Mali (ML), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Netherlands (NL), New Zealand (NZ), Niger (NE), Norway (NO), Poland (PL), Portugal (PT), Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Saint Lucia (LC), Senegal (SN), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Tajikistan (TJ), Togo

(TG), Trinidad and Tobago (TT), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Yugoslavia (YU), and Zimbabwe (ZW), [subsequently identified as International Patent Application _____, filed _____*], including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of VERTEX PHARMACEUTICALS INCORPORATED its designee, or in my/our names at VERTEX PHARMACEUTICALS INCORPORATED, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue on the aforesaid inventions, discoveries and applications in any country of the world and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the following priority application(s):

<u>60/147,706</u>	<u>U.S.A.</u>	<u>August 8, 1999</u>
application no.	country	filing date

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

I/We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in any country throughout the world to VERTEX PHARMACEUTICALS INCORPORATED as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.

I/We agree, at any time, upon the request of VERTEX PHARMACEUTICALS INCORPORATED to execute and to deliver to VERTEX PHARMACEUTICALS INCORPORATED any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

I/We further agree, at any time, upon request of VERTEX PHARMACEUTICALS INCORPORATED to execute and to deliver to VERTEX PHARMACEUTICALS INCORPORATED such additional documents, if any, as are necessary or desirable to secure patent protection on said

* I/We hereby authorize Vertex Pharmaceuticals Incorporated and its representatives to insert in this instrument the International Patent Application number and the filing date of said application when Vertex Pharmaceuticals Incorporated is officially notified thereof.

inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect any and all rights of VERTEX PHARMACEUTICALS INCORPORATED under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

ASSIGNORS:

- _____ (1) Julian Golec
- _____ (2) Paul Charifson
- _____ (3) Guy Brenchley

Julian Golec
Paul Charifson
Guy Brenchley

On this 24th day of July, 2000,

(1) Julian Golec personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts, and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.

Phyllis A. Tobey
Notary Public

PHYLLIS A. TOBEY
Notary Public

On this 24th day of July, 2000,

(2) Paul Charifson personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts, and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.

My Commission Expires May 8, 2003

Phyllis A. Tobey
Notary Public

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8, 2003

On this 24th day of July, 2000,


(3) Guy Brenchley personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts, and executed the foregoing Assignment and duly acknowledged to me that such Assignment was executed for the uses and purposes therein expressed.

Phyllis A. Tobey
Notary Public

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8, 2003


ACKNOWLEDGEMENT OF ASSIGNEE:

Vertex Pharmaceuticals Incorporated

By: 
Andrew S. Marks, Esq.
Chief Patent Counsel

On this 24th day of July, 2000,

Andrew S. Marks personally appeared before me, a Notary Public in and for the Commonwealth of Massachusetts, and duly acknowledged the executed Assignment on behalf of the Assignee.

Notary Public 

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8, 2003